GE Healthcare Technologies GEHC · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
84.03
+2.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$20.63bn
FY2019FY2025
Net income
$2.08bn
FY2019FY2025
Free cash flow
$1.51bn
FY2019FY2025
Shareholders' equity
$10.38bn
FY2019FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $20.63bn | $19.67bn | $19.55bn | $18.34bn | $17.59bn | $17.16bn | $16.63bn |
| Gross profit | $8.25bn | $8.21bn | $7.92bn | $7.18bn | $7.17bn | $6.77bn | $6.55bn |
| Research and development | $1.26bn | $1.31bn | $1.21bn | $1.03bn | $816.0m | $810.0m | $833.0m |
| Operating income | $3.16bn | $2.63bn | $2.44bn | $2.52bn | $2.80bn | $2.72bn | $2.12bn |
| Net income | $2.08bn | $1.99bn | $3.10bn | $1.92bn | $2.25bn | $13.85bn | $1.52bn |
| Diluted earnings per share | 4.53 | 4.34 | 6.78 | 4.22 | 4.94 | 30.45 | 3.35 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Total assets | $36.91bn | $33.09bn | $32.45bn | $27.54bn | $26.31bn | $24.23bn | — |
| Cash and short-term investments | $4.51bn | $2.89bn | $2.50bn | $1.45bn | $556.0m | $1.01bn | — |
| Total liabilities | $26.31bn | $24.44bn | $25.14bn | $17.95bn | $9.41bn | $9.25bn | — |
| Debt | $10.04bn | $8.99bn | $9.44bn | $8.25bn | $37.0m | $35.0m | — |
| Shareholders' equity | $10.38bn | $8.45bn | $7.13bn | $9.36bn | $16.66bn | $14.73bn | — |
| Shares outstanding | 460m | 459m | 458m | 454m | 455m | 455m | 455m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | $1.99bn | $1.95bn | $2.10bn | $2.11bn | $1.61bn | $1.69bn | $1.99bn |
| Capital spending | −$482.0m | −$401.0m | −$387.0m | −$310.0m | −$248.0m | −$259.0m | −$331.0m |
| Free cash flow | $1.51bn | $1.55bn | $1.71bn | $1.80bn | $1.36bn | $1.43bn | $1.66bn |
| Dividends paid | −$64.0m | −$55.0m | −$41.0m | — | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.29bn | $5.13bn | $4.67bn | $5.14bn | $5.01bn | $4.78bn | $5.32bn | $4.86bn |
| Gross profit | $2.18bn | $1.98bn | $2.54bn | $1.99bn | $1.99bn | $2.01bn | $2.27bn | $2.03bn |
| Operating income | $739.0m | $515.0m | $664.0m | $653.0m | $654.0m | $740.0m | $912.0m | $676.0m |
| Net income | $573.0m | $389.0m | $184.0m | $446.0m | $486.0m | $564.0m | $720.0m | $471.0m |
| Diluted earnings per share | 1.26 | 0.86 | 0.40 | 0.97 | 1.06 | 1.23 | 1.57 | 1.03 |
| Cash from operations | −$517.0m | $290.0m | $1.05bn | $593.0m | $94.0m | $250.0m | $913.0m | $738.0m |
| Capital spending | −$100.0m | −$178.0m | −$134.0m | −$110.0m | −$86.0m | −$152.0m | −$102.0m | −$90.0m |
| Free cash flow | −$617.0m | $112.0m | $917.0m | $483.0m | $8.0m | $98.0m | $811.0m | $648.0m |
| Total assets | $37.25bn | $37.13bn | $36.91bn | $36.13bn | $35.50bn | $33.59bn | $33.09bn | $33.85bn |
| Cash and short-term investments | $2.10bn | $2.29bn | $4.51bn | $4.00bn | $3.76bn | $2.47bn | $2.89bn | $3.57bn |
| Debt | $10.09bn | $10.27bn | $10.00bn | $10.42bn | $10.53bn | $8.88bn | $9.07bn | $10.43bn |
| Shareholders' equity | $10.97bn | $10.67bn | $10.38bn | $9.99bn | $9.71bn | $9.19bn | $8.45bn | $8.32bn |
Financial ratios
Data as of 20 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 40.0% | 41.7% | 40.5% | 39.1% | 40.8% | 39.4% |
| Operating margin | 15.3% | 13.3% | 12.5% | 13.8% | 15.9% | 15.8% |
| Net margin | 10.1% | 10.1% | 15.9% | 10.4% | 12.8% | 80.7% |
| Return on equity | 20.1% | 23.6% | 43.5% | 20.5% | 13.5% | 94.0% |
| Return on assets | 5.6% | 6.0% | 9.6% | 7.0% | 8.5% | 57.1% |
| Free cash flow yield | 8.4% | 8.0% | 8.5% | 8.3% | 6.4% | — |
| Revenue growth | 4.8% | 0.6% | 6.6% | 4.3% | 2.5% | 3.2% |
| Earnings growth | 4.6% | -35.8% | 62.0% | -14.7% | -83.8% | 808.5% |
| Current ratio | 1.18x | 1.00x | 1.00x | 1.09x | 0.97x | 0.84x |
| Debt to equity | 0.96x | 1.07x | 1.34x | 0.89x | 0.01x | 0.01x |
| Equity ratio | 28.1% | 25.5% | 22.0% | 34.0% | 63.3% | 60.8% |
| Interest coverage | 7.02x | 5.20x | 4.49x | 29.33x | 70.03x | 41.21x |
| R&D as a share of sales | 6.1% | 6.7% | 6.2% | 5.6% | 4.6% | 4.7% |
| Buybacks as a share of market value | -0.3% | -0.2% | -0.9% | 0.2% | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 3.4% | 3.4% | — |
| Operating income | 7.8% | 3.1% | — |
| Net income | 2.8% | -31.5% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 40.8% | 40.4% | 40.3% | — |
| Operating margin | 14.4% | 13.7% | 14.4% | — |
| Net margin | 10.1% | 11.6% | 22.3% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Price to earnings | 18.1 | 18.0 | 11.4 | 13.8 |
| Price to sales | 1.9 | 1.9 | 1.9 | 1.4 |
Market value over time
30 Dec 2022 to 18 Sept 2026, in USD
$26.50bn$29.12bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Return | 7% | 2% | 34% | -6% |
Dividends and splits
Per share, in the currency the company pays
Paid for 3 years. Last went ex-dividend on 23 Oct 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Paid in the year | 0.11 | 0.14 | 0.125 | 0.12 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.